[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1298
1. Schiefke I, Neumann S, Zabel-Langhennig A, Moessner J, Caca K: Use of an endoscopic suturing device (the "ESD") to treat patients with gastroesophageal reflux disease, after unsuccessful EndoCinch endoluminal gastroplication: another failure. Endoscopy; 2005 Aug;37(8):700-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study involved 20 patients with gastroesophageal reflux disease (GERD), who had been initially treated with an EndoCinch procedure, but had relapsed after a median of 7.5 months, with lost or dysfunctional sutures and with reflux symptoms that required proton pump inhibitor (PPI) treatment.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Manometry. Middle Aged. Prospective Studies. Proton Pump Inhibitors. Treatment Failure


2. Rick O, Braun T, Siegert W, Beyer J: Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer; 2006 Aug;42(12):1775-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was assess the activity of thalidomide in patients with progressive relapsed or platinum-refractory germ-cell tumours (GCT).
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / etiology. Platinum Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765039.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


3. Reilly KM, Kisor DF: Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther; 2009;2:219-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
  • Therefore, this unique drug feature of nelarabine accounts for clinical utilization in treating adult and pediatric patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1993 Aug;7(8):1261-7 [8350627.001]
  • [Cites] Ann N Y Acad Sci. 1993 Jun 23;685:225-36 [8363226.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2107-13 [9815603.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4937-43 [10519407.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):995-1003 [10694549.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:123-30 [16304369.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):535-40 [17158775.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1098-105 [18309944.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1842-8 [12750168.001]
  • (PMID = 20616909.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2886323
  • [Keywords] NOTNLM ; 9-beta-D-arabinofuranosyl guanine / T-cell acute lymphoblastic leukemia / ara-G / nelarabine
  •  go-up   go-down


Advertisement
4. Balmford J, Borland R, Benda P: Patterns of use of an automated interactive personalized coaching program for smoking cessation. J Med Internet Res; 2008;10(5):e54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Those who had recently relapsed to smoking following a quit attempt made up 37%.
  • [MeSH-minor] Adult. Aged. Automation. Disease Progression. Female. Health Promotion. Humans. Male. Middle Aged. Recurrence. Time Factors. Treatment Failure. Treatment Outcome. Victoria. Young Adult

  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Respiration. 2002;69(2):111-4 [11961422.001]
  • [Cites] Drug Alcohol Rev. 2009 Jan;28(1):66-72 [19320678.001]
  • [Cites] J Am Med Inform Assoc. 2003 Jan-Feb;10(1):16-20 [12509354.001]
  • [Cites] Addiction. 2003 Jun;98(6):837-46 [12780372.001]
  • [Cites] Addiction. 2004 Jan;99(1):29-38 [14678060.001]
  • [Cites] Addiction. 2004 Mar;99(3):369-77 [14982550.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(3):CD000146 [15266423.001]
  • [Cites] Prev Med. 2004 Nov;39(5):962-8 [15475030.001]
  • [Cites] Am Psychol. 1992 Sep;47(9):1102-14 [1329589.001]
  • [Cites] Br Med Bull. 1996 Jan;52(1):12-21 [8746293.001]
  • [Cites] Health Psychol. 1998 May;17(3):290-9 [9619480.001]
  • [Cites] Tob Control. 2004 Dec;13(4):415-21 [15564628.001]
  • [Cites] Nicotine Tob Res. 2004 Dec;6 Suppl 3:S311-21 [15799594.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(2):CD001292 [15846616.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(3):CD001118 [16034855.001]
  • [Cites] Tob Control. 2005 Aug;14(4):255-61 [16046689.001]
  • [Cites] J Med Internet Res. 2007;9(3):e28 [17942390.001]
  • [Cites] Tob Control. 2002 Jun;11 Suppl 2:ii74-5 [12034987.001]
  • (PMID = 19097975.001).
  • [ISSN] 1438-8871
  • [Journal-full-title] Journal of medical Internet research
  • [ISO-abbreviation] J. Med. Internet Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2630829
  •  go-up   go-down


5. Zhang H, Leng P, Wang Y: [Comparative study on repair of medium and large-sized osteochondral compound defects with mosaicplasty]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Apr;21(4):378-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-four adult goats were divided into 3 groups randomly.
  • But in the large-sized defect groups, some of the osteochondral plugs were relapsed into the defects leaving the recipient sites some steps, leading to some degree of abrasion in the opposing articular cartilage.

  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • MedlinePlus Health Information. consumer health - Knee Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546883.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteoglycans
  •  go-up   go-down


6. Ferrari FS, Stella A, Pasquinucci P, Vigni F, Civeli L, Pieraccini M, Magnolfi F: Treatment of small hepatocellular carcinoma: a comparison of techniques and long-term results. Eur J Gastroenterol Hepatol; 2006 Jun;18(6):659-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography scan showed that complete necrosis was achieved in 81% of treated nodules (120 out of 148); as a whole, the disease relapsed in 42 (32.0%) patients (with a disease-free interval of 17.0+/-13.7 months).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Injections, Intradermal. Liver Cirrhosis / complications. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702857.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3K9958V90M / Ethanol
  •  go-up   go-down


7. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL, Children's Oncology Group: A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Apr;50(4):788-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study.
  • BACKGROUND: This report summarizes a phase 1 study conducted by the Children's Cancer Group (CCG) to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and anti-leukemia activity of paclitaxel in children with advanced stage leukemias.
  • RESULTS: Sixty-three patients (median 10 years) with refractory or relapsed leukemia (ALL) (n = 39), acute myeloid leukemia (AML) (n = 19), biphenotypic (n = 4), and JCML (n = 1)) were enrolled.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17668866.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / K23 CA113775; United States / NCI NIH HHS / CA / U01 CA097452; United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01-CA97452; United States / NCI NIH HHS / CA / K23-CA113775; United States / NCI NIH HHS / CA / K12-CA90433; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCRR NIH HHS / RR / MO1 RR00108
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG: Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res; 2010 Feb 1;16(3):1033-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
  • Based on preclinical studies, we conducted a phase II clinical trial testing the efficacy and safety of the Akt inhibitor perifosine in patients with relapsed/refractory WM.
  • CONCLUSION: Perifosine resulted in at least a minimal response in 35% of patients and a median progression-free survival of 12.6 months in patients with relapsed or relapsed/refractory WM, as well as in vivo inhibition of pGSK activity.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 May 15;107(10):4053-62 [16418332.001]
  • [Cites] Ann Oncol. 1995 Jan;6(1):49-52 [7710983.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3320-5 [17545538.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2337-45 [17699729.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4417-26 [17761832.001]
  • [Cites] Blood. 2008 May 15;111(10):5068-77 [18334673.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4163-70 [19196866.001]
  • [Cites] Blood. 2009 Sep 17;114(12):2375-85 [19617573.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):214-26 [10623712.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1439-45 [11282020.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3596-601 [11504741.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):132-8 [15598950.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1564-77 [15735132.001]
  • [Cites] Clin Lymphoma. 2005 Mar;5(4):215-6 [15794850.001]
  • [Cites] Haematologica. 2005 Dec;90(12):1655-8 [16330439.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Mar;6(5):380-3 [16640813.001]
  • [Cites] Eur J Cancer. 2002 Aug;38(12):1615-21 [12142051.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6587-97 [12242656.001]
  • [Cites] Anticancer Drugs. 2003 Feb;14(2):167-73 [12569304.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):116-20 [12720119.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):121-6 [12720120.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):127-31 [12720121.001]
  • [Cites] Lancet Oncol. 2003 Nov;4(11):679-85 [14602248.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):193-204 [15023437.001]
  • [Cites] Curr Treat Options Oncol. 2004 Jun;5(3):239-47 [15115652.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv233-9 [15477314.001]
  • [Cites] Am J Med. 1993 Jul;95(1):49-52 [8328496.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1570-5 [17353550.001]
  • (PMID = 20103671.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA126119-02; United States / NCI NIH HHS / CA / R21 CA126119-01A1; United States / NCI NIH HHS / CA / CA126119-02; United States / NCI NIH HHS / CA / R21 CA126119-01; United States / NCI NIH HHS / CA / R21 CA126119
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oligopeptides; 107-73-3 / Phosphorylcholine; 2GWV496552 / perifosine; 99278-03-2 / GSK peptide; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS164533; NLM/ PMC2885252
  •  go-up   go-down


9. Levenga H, Woestenenk R, Schattenberg AV, Maas F, Jansen JH, Raymakers R, De Mulder PH, van de Wiel-van Kemenade E, Schaap N, de Witte T, Dolstra H: Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. Bone Marrow Transplant; 2007 Sep;40(6):585-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
  • Donor lymphocyte infusion (DLI) after allogeneic SCT induces complete remissions in approximately 80% of patients with relapsed CML in chronic phase, but some patients do not respond to DLI.
  • Our data suggest that the combination of donor T cells and mixed chimerism in DC subsets induces a potent graft-versus-leukemia (GVL) effect in association with GVHD.
  • [MeSH-major] Dendritic Cells / immunology. Graft vs Leukemia Effect / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Lymphocyte Transfusion. T-Lymphocytes / immunology. Transplantation Chimera / immunology
  • [MeSH-minor] Adult. Aged. Blood Donors. Female. Graft vs Host Disease / immunology. Humans. Lymphocyte Count. Male. Middle Aged. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637687.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Fang J, Ma D, Zhong J, Zhu B, Ding GH, Fu LM, Cui CL, Han JS: [Prospective study of Han's acupoint nerve stimulator for preventing relapse of detoxified heroin addicts]. Zhonghua Yi Xue Za Zhi; 2010 Jun 1;90(21):1472-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 164 rehabilitating former heroin addicts, 53 remained drug-free at the end of 12 months observation period as judged by negative urinalysis while 35 become relapsed as documented by positive urine tests.
  • The rest 76 dropped off due to various reasons and were all counted into the category of "relapsed".
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prospective Studies. Recurrence. Young Adult

  • MedlinePlus Health Information. consumer health - Heroin.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973218.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


11. Grandics P: Complete remission achieved in a case of both primary and recurrent adult acute myelogeneous leukemia by a novel nutritional therapy. J Altern Complement Med; 2006 Apr;12(3):311-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission achieved in a case of both primary and recurrent adult acute myelogeneous leukemia by a novel nutritional therapy.
  • OBJECTIVES: The aim of this study was to determine the possible clinical benefit of molasses-based dietary compositions (designated as MSQ 13, MSQ 15, and MSQ 18) in a case of both primary and recurrent adult AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / diet therapy. Molasses. Nutrition Therapy / methods
  • [MeSH-minor] Adult. Female. Humans. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16646731.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Asero R, Tedeschi A: Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol; 2010;20(5):386-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We studied 750 adult patients with CU and prescribed a course of oral corticosteroids (starting with prednisone 25 mg/day for 3 days) to those who reported little or partial response to antihistamine treatment.
  • Thirty-five patients responded well but relapsed when prednisone doses were tapered or shortly after withdrawal.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Chronic Disease. Clinical Protocols. Drug Resistance. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies


13. Hallack Neto AE, Pereira J, Beitler B, Chamone DA, Llacer PD, Dulley FL, Macedo MC, Chaoubah A: Results of CHOP chemotherapy for diffuse large B-cell lymphoma. Braz J Med Biol Res; 2006 Oct;39(10):1315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary refractory patients and relapsed patients were also assessed.
  • Eleven of 50 refractory and relapsed patients were consolidated with high doses of chemotherapy.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906323.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, Prince HM, Wolf M, Clarke K, Underhill C, Mills T, Mollee P, Gill D, Marlton P, Seymour JF, Khanna R: Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res; 2006 Jan 15;12(2):460-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 58 patients with HL (31 newly diagnosed, 6 relapsed, and 21 in long-term remission) were tested.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Genome, Viral. Humans. Male. Middle Aged. Monocytes / virology. Polymerase Chain Reaction. Prognosis. Prospective Studies. Remission Induction. Risk Factors. Sensitivity and Specificity. Viral Load

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428487.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral
  •  go-up   go-down


15. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME: Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol; 2006 Jul 1;24(19):3150-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
  • PURPOSE: To compare conventional sibling bone marrow transplantation (CBMT), BMT with alternative donor (ABMT), and chemotherapy (CT) for children with acute lymphoblastic leukemia (ALL) and an early first marrow relapse.
  • Of these, five patients died after BMT and 5 patients relapsed.
  • CONCLUSION: More than one half of patients died, failed reinduction, or relapsed again before 3 months after CR2 (median time to BMT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / surgery. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Siblings. Survival Analysis. Transplantation, Homologous. Treatment Outcome


16. Papiani G, Einhorn LH: Salvage chemotherapy with high-dose carboplatin plus etoposide and autologous peripheral blood stem cell transplant in male pure choriocarcinoma: a retrospective analysis of 13 cases. Bone Marrow Transplant; 2007 Aug;40(3):235-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One additional patient who relapsed after HDCT and was treated with third line chemotherapy followed by two surgical resections of choriocarcinoma is currently alive NED at +90 months from HDCT.
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Chorionic Gonadotropin / blood. Disease-Free Survival. Etoposide / administration & dosage. Hematologic Neoplasms / blood. Hematologic Neoplasms / therapy. Hematologic Neoplasms / ultrasonography. Humans. Male. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Autologous. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17563738.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


17. Uckun FM, Morar S, Qazi S: Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukaemias. Br J Haematol; 2006 Nov;135(4):500-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study examined the ability of the semi-synthetic vinca alkaloid, Vinorelbine/Navelbine, to cause apoptotic death in freshly obtained primary leukaemia cells from 53 patients with haematological malignancies, including 22 patients with acute lymphoblastic leukaemia (ALL), 24 patients with chronic lymphocytic leukaemia (CLL), three patients with chronic myeloid leukaemia in blast crisis (CML-BC) and four patients with acute myeloid leukaemia (AML).
  • Objective responses, including complete remission (CR) and CR with incomplete haematological recovery, were achieved in 12 of 17 (71%) patients with aggressive and therapy-refractory leukaemias, including five of nine patients with relapsed ALL, three of three patients with CML-BC and four of five patients with rapidly progressive CLL, who were treated with a vinorelbine-based salvage chemotherapy regimen.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia / drug therapy. Salvage Therapy / methods. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Apoptosis / drug effects. Child. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor / methods. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061978.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


18. Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, Capurso L: Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci; 2010 Jul;55(7):2002-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within 12 months, 37/64 patients (58%) had prolonged steroid-free remission, while 11/64 (17%) relapsed.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Aspirin / administration & dosage. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Multivariate Analysis. Probability. Recurrence. Remission Induction. Retrospective Studies. Risk Assessment. Severity of Illness Index. Statistics, Nonparametric. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2478-85 [16279903.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1263-76 [10811338.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jan;1(1):36-43 [15017515.001]
  • [Cites] Adv Ther. 2001 Nov-Dec;18(6):261-71 [11841196.001]
  • [Cites] Inflamm Bowel Dis. 2008 Aug;14 (8):1133-8 [18314901.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jun;16(6):1109-16 [12030952.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000543 [16625536.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jun 15;17(12):1471-80 [12823149.001]
  • [Cites] Gut. 2005 Jul;54(7):960-5 [15951542.001]
  • [Cites] BMJ. 1989 Jan 14;298(6666):82-6 [2563951.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Jul 1;26(1):21-9 [17555418.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:10-6 [16939424.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1628-36 [10925961.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1371-85 [15233681.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct;20 Suppl 4:88-92 [15352901.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1607-17 [12135008.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1998 Jun;30(3):254-7 [9759590.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1867-71 [9382054.001]
  • [Cites] Aliment Pharmacol Ther. 1995 Jun;9(3):293-300 [7654892.001]
  • [Cites] Inflamm Bowel Dis. 2006 Oct;12(10):979-94 [17012969.001]
  • [Cites] J Crohns Colitis. 2008 Mar;2(1):24-62 [21172195.001]
  • [Cites] Gut. 2004 Sep;53 Suppl 5:V1-16 [15306569.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Feb;15(2):251-6 [11148445.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):329-37 [17347061.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 1;23(7):841-55 [16573787.001]
  • [Cites] Can J Gastroenterol. 2007 Dec;21(12):827-34 [18080055.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:37-40 [16961743.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Apr;12(4):361-6 [9690726.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4):291-7 [15758622.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Nov 1;26(9):1179-86 [17944732.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jul 15;24(2):319-30 [16842459.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):255-60 [11487534.001]
  • [Cites] Postgrad Med J. 1975;51 Suppl 4:20-5 [1105513.001]
  • (PMID = 19937467.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] KGZ1SLC28Z / Beclomethasone; R16CO5Y76E / Aspirin
  •  go-up   go-down


19. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma; 2006 Aug;47(8):1545-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
  • Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of patients will experience relapse following ASCT.
  • We conducted a phase II study in 40 patients with relapsed/refractory HD (n = 18) and NHL (n = 22) using HDSC followed by ASCT.
  • At a median follow-up of 32 months (range, 3 - 61), nine patients relapsed/progressed and eleven patients died.
  • [MeSH-minor] Adolescent. Adult. Etoposide / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966265.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


20. Sivapathasingam V, Harvey MP, Wilson RB: Helicobacter pylori eradication: a novel therapeutic option in chronic immune thrombocytopenic purpura. Med J Aust; 2008 Oct 6;189(7):367-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient had an initial response at 3 months (15 x 10(9)/L to 208 x 10(9)/L), but relapsed 4 months after H. pylori eradication and underwent splenectomy with platelet count recovery.
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Anti-Ulcer Agents / therapeutic use. Australia. Chronic Disease. Drug Therapy, Combination. Female. Hospitals, Teaching. Humans. Male. Medical Records. Middle Aged. Retrospective Studies. Splenectomy. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Immune Thrombocytopenic Purpura.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837678.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents
  •  go-up   go-down


21. Feige B, Scaal S, Hornyak M, Gann H, Riemann D: Sleep electroencephalographic spectral power after withdrawal from alcohol in alcohol-dependent patients. Alcohol Clin Exp Res; 2007 Jan;31(1):19-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our hypothesis was that the subgroup of patients who relapsed within the 3 months to follow-up would exhibit-increased dysfunctional arousal manifested by higher-frequency (beta) EEG power during sleep.
  • At the 3-month clinical follow-up assessment, 12 of them had relapsed and 14 abstained.
  • [MeSH-minor] Adult. Aging / physiology. Aging / psychology. Body Mass Index. Depression / psychology. Electromyography. Female. Humans. Male. Middle Aged. Movement / physiology. Polysomnography. Psychiatric Status Rating Scales. Sex Characteristics. Sleep, REM / physiology

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207097.001).
  • [ISSN] 0145-6008
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 3K9958V90M / Ethanol
  •  go-up   go-down


22. Arenberger P, Arenbergerova M, Vohradnikova O, Kremen J: Early detection of melanoma progression by quantitative real-time RT-PCR analysis for multiple melanoma markers. Keio J Med; 2008 Mar;57(1):57-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the above group, 27 % of subjects relapsed during the study.
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Early Diagnosis. Eukaryotic Initiation Factor-3 / genetics. Female. Genetic Markers. Genetic Testing / methods. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382126.001).
  • [ISSN] 0022-9717
  • [Journal-full-title] The Keio journal of medicine
  • [ISO-abbreviation] Keio J Med
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / EIF3A protein, human; 0 / Eukaryotic Initiation Factor-3; 0 / Genetic Markers
  •  go-up   go-down


23. Wang Y, Liu KY, Xu LP, Liu DH, Chen H, Han W, Chen YH, Shi HX, Zhang YC, Wang JZ, Zhang XU, Chen Y, Huang XJ, Lu DP: [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia]. Zhonghua Nei Ke Za Zhi; 2007 Nov;46(11):903-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
  • OBJECTIVE: To retrospectively analyze the results of a consecutive series of 90 refractory/relapsed acute leukemia (AL) patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) in our center.
  • METHODS: Of the 90 refractory/relapsed AL patients, 56 were male and 34 female, with a median age of 37 (13 - 59) years.
  • Among them, 73 patients suffered from AL including 11 Ph+ acute lymphoid leukemia in first complete remission, 23 in second or greater complete remission, 39 in non-remission or relapse and 17 patients suffered from myelodysplastic syndrome (MDS-RAEB or RAEB-T) before transplant.
  • RESULTS: At the last follow-up, 56/90 (62.2%) survived, 50/90 (55.5%) survived without leukemia and 28/90 (31.1%) relapsed.
  • The 4-year OS and DFS were significantly higher for patients in CR (54.0%) or MDS (70.1%) than in non-remission and relapsed (28.2%) patients before allo-HSCT (P = 0.027).
  • The outcome of grade 0-I acute GVHD was better than that of II-IV GVHD (57.6% vs 26.7%, P = 0.015).
  • Sex, age, central nervous system leukemia, conditioning regimen and the source of stem cell were not the factors affecting OS, DFS, cumulative incidences of relapse rate and treatment related mortality.
  • CONCLUSIONS: allo-HSCT can cure a significant proportion of refractory/relapsed AL patients, especially for those in CR.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia / surgery
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cyclosporine / therapeutic use. Female. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Multivariate Analysis. Myelodysplastic Syndromes / surgery. Retrospective Studies. Risk Factors. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Homologous


24. Bieber MM, Twist CJ, Bhat NM, Teng NN: Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro. Pediatr Blood Cancer; 2007 Apr;48(4):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
  • This study investigated if this mAb could bind and kill acute lymphoblastic leukemia (ALL) B-progenitor lymphoblasts in vitro.
  • Based on the results from this preclinical study, a Phase I clinical trial with mAb 216 for the treatment of patients with relapsed or refractory B-lineage ALL is ongoing.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow / immunology. Bone Marrow / pathology. Cell Line, Tumor / drug effects. Cell Line, Tumor / immunology. Child. Complement System Proteins / immunology. Drug Screening Assays, Antitumor. Hematopoietic Stem Cells / drug effects. Hematopoietic Stem Cells / immunology. Humans. Immunophenotyping. Immunotherapy. Leukemia, Myeloid / immunology. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / pathology. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / immunology. Specimen Handling. Tissue Preservation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421902.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


25. Rubello D, Fanti S, Nanni C, Farsad M, Castellucci P, Boschi S, Franchi R, Mariani G, Fig LM, Gross MD: 11C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. Eur J Nucl Med Mol Imaging; 2006 Apr;33(4):453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients developed post-parathyroidectomy hypoparathyroidism and one patient with normocalcaemic HPT relapsed 8 months after surgery.
  • [MeSH-minor] Adult. Aged. False Negative Reactions. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Positron-Emission Tomography / methods. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucl Med Commun. 2003 Jan;24(1):85-90 [12501024.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Oct;31(10 ):1405-12 [15278308.001]
  • [Cites] Nucl Med Commun. 2005 Feb;26(2):133-6 [15657506.001]
  • [Cites] Acta Isot (Padova). 1965 Dec 30;5(4):337-45 [5872386.001]
  • [Cites] J Nucl Med. 1996 Nov;37(11):1766-70 [8917171.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):25-8 [9022764.001]
  • [Cites] Arch Surg. 2004 Aug;139(8):838-42; discussion 842-3 [15302692.001]
  • [Cites] Int J Urol. 2003 Jan;10(1):7-11; discussion 12 [12534918.001]
  • [Cites] J Nucl Med. 1996 May;37(5):798-804 [8965148.001]
  • [Cites] Nucl Med Commun. 2003 Feb;24(2):125-31 [12548036.001]
  • [Cites] Rev Med Liege. 1968 Oct;:Suppl 1:255+ [5712330.001]
  • [Cites] J Am Coll Surg. 2004 Aug;199(2):229-33 [15275878.001]
  • [Cites] Surgery. 1994 Dec;116(6):974-81 [7985105.001]
  • [Cites] Clin Nucl Med. 2003 Dec;28(12 ):955-60 [14663315.001]
  • [Cites] J Nucl Med. 1971 Nov;12(11):751-3 [5113639.001]
  • [Cites] World J Surg. 2004 Jan;28(1):100-7 [14639488.001]
  • [Cites] Surgery. 2000 Jul;128(1):29-35 [10876182.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):220-6 [15695779.001]
  • [Cites] Eur J Endocrinol. 1998 Aug;139(2):195-7 [9724076.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):568-80 [15294882.001]
  • [Cites] Semin Nucl Med. 1985 Apr;15(2):161-70 [2988130.001]
  • [Cites] Ann Surg. 1965 Sep;162(3):492-504 [5829722.001]
  • [Cites] Dtsch Med Wochenschr. 1965 Dec 31;90(53):2353-4 [5851935.001]
  • [Cites] Med Klin. 1967 Apr 28;62(17):672-4 [5595336.001]
  • [Cites] Minerva Endocrinol. 2004 Dec;29(4):189-93 [15765028.001]
  • [Cites] Eur J Nucl Med. 1997 Dec;24(12 ):1494-8 [9391184.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jun;18 Suppl 3:iii71-5 [12771306.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):198-9 [15695775.001]
  • (PMID = 16435115.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; 971Z4W1S09 / Technetium Tc 99m Sestamibi; AE28F7PNPL / Methionine
  •  go-up   go-down


26. Zhan Y, Feng R, Yi ZS, Song LL, Wang Q, Xu M, Wei YQ: Simultaneous analysis of telomere length and cell surface antigen in leukemia by multicolor Flow-FISH. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec;18(6):1395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous analysis of telomere length and cell surface antigen in leukemia by multicolor Flow-FISH.
  • This study was purposed to explore the feasibility of simultaneous analysis of telomere length and cell surface antigen by multicolor Flow-FISH to assess minimal residual disease (MRD) in leukemia.
  • The telomere length in 34 leukemia patients versus 20 normal controls was compared by using Flow-FISH, and the relationship between telomere length and therapeutic effect and prognosis was analyzed preliminarily.
  • The results indicated that the telomere length of de novo patients was significantly shorter than that of controls except the patients in chronic myeloid leukemia-chronic phase (CML-CP).
  • The shorter telomere, the lower complete remission (CR) rates were observed in acute leukemia cases and the shorter duration of CP before onset of blast phase (BP) occurred in CML cases.
  • The acute leukemia patients showed longer telomere and fewer cells expressed the related antigen after CR.
  • However, the telomere of relapsed cases shortened again after relapse with elevated specific antigen expression.
  • In the relapsed cases, the telomere of related antigen positive cells shortened ahead of telomere length change of the whole cells and morphologic change of bone marrow cells.
  • It is concluded that analysis of telomere length by flow-FISH manifests the significance for monitoring disease conditions, estimating prognosis and guiding therapy in all kinds of leukemia.
  • The simultaneous analysis of telomere length and cell surface antigen by multicolor flow-FISH may monitor abnormal clone or clonal evolution to predict recurrence more sensitively and specifically, and may provide a promising and widely applicable method for monitoring MRD in leukemia.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176337.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Surface
  •  go-up   go-down


27. Schrader AJ, Ohlmann CH, Rossmanith S, Hofmann R, Heidenreich A: Impact of evidence-based interdisciplinary guidelines on testis cancer management. Cancer; 2006 Jan 15;106(2):313-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Group A, 19/234 (8.1%) patients relapsed and 53% of these patients had been treated insufficiently (P < 0.005).
  • As of this writing, only 3 of 84 (3.6%) patients in Group B have relapsed, and no patient has died because of tumor or consecutive treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Evidence-Based Medicine. Humans. Male. Middle Aged. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342064.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ray D, Goswami R, Dadhwal V, Goswami D, Banerjee U, Kochupillai N: Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis. J Infect; 2007 Oct;55(4):374-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the patients relapsed with no change in Candida species.
  • CONCLUSION: The results of the current study indicating comparable mycological cure rate at 3 months between fluconazole and boric acid treated patients would support use of boric acid in the acute management of VVC in view of its superior short term response in diabetic women with C. glabrata infections.
  • [MeSH-minor] Administration, Oral. Adult. Female. Fluconazole / administration & dosage. Humans. Middle Aged. Prospective Studies. Suppositories. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692922.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Boric Acids; 0 / Suppositories; 8VZV102JFY / Fluconazole; R57ZHV85D4 / boric acid
  •  go-up   go-down


29. Misch D, Steffen IG, Schönberger S, Voelker T, Furth C, Stöver B, Hautzel H, Henze G, Amthauer H, Denecke T: Use of positron emission tomography for staging, preoperative response assessment and posttherapeutic evaluation in children with Wilms tumour. Eur J Nucl Med Mol Imaging; 2008 Sep;35(9):1642-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this study, 23 FDG-PET examinations in 12 paediatric patients (female, n = 5; male, n = 7; age, 1-19 years) with WT (primary, n = 9; relapsed, n = 3) were analysed.
  • RESULTS: FDG-PET and CIM showed concordant results for staging of primary WT, whereas FDG-PET was superior in 1/3 cases with recurrent WT.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Recurrence, Local. Recurrence

  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 May;15(5):808-20 [15111352.001]
  • [Cites] Clin Nucl Med. 2003 Oct;28(10 ):815-20 [14508272.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2554-62 [16904312.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):192-8 [11990305.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jul-Aug;19(4):334-8 [9256833.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):311-9 [11332141.001]
  • [Cites] J Nucl Med. 2000 Oct;41(10 ):1695-701 [11038000.001]
  • [Cites] Pediatr Radiol. 2006 Jun;36(6):524-31 [16622665.001]
  • [Cites] Cancer. 2002 Jun 15;94(12 ):3277-84 [12115361.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1187-90 [2162911.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1229-35 [15464183.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):132-40 [15175957.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5435-41 [18048826.001]
  • [Cites] Eur J Nucl Med. 2000 Sep;27(9):1305-11 [11007511.001]
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):183-90 [10696124.001]
  • [Cites] Clin Nucl Med. 2000 Nov;25(11):874-81 [11079583.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8828-34 [16314643.001]
  • [Cites] Radiology. 1997 Sep;204(3):627-33 [9280236.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):607-11 [16261559.001]
  • [Cites] Ann Oncol. 2001 Apr;12 (4):479-86 [11398879.001]
  • [Cites] Onkologie. 2003 Oct;26(5):489-93 [14605468.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1279-87 [10778952.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Aug;28(8):501-12 [16912590.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Dec;9(6):1287-302 [8591966.001]
  • [Cites] J Clin Oncol. 1989 May;7(5):638-47 [2540289.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):327-33 [16307418.001]
  • [Cites] Nucl Med Commun. 2006 Jan;27(1):17-24 [16340719.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):131-6 [17084075.001]
  • [Cites] Cancer. 1976 Aug;38(2):647-54 [184913.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):550-6 [10215835.001]
  • [Cites] Oncologist. 2005 Nov-Dec;10(10):815-26 [16314292.001]
  • (PMID = 18509634.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


30. Katoch K, Katoch VM, Natarajan M, Gupta UD, Sharma VD, Singh HB: Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin. Indian J Lepr; 2008 Oct-Dec;80(4):331-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The relapsed patients presented with the appearance of new lesions, slit-skin smears were again found to become positive after becoming negative.
  • Three of the four cases who relapsed had the initial mean BI of 2 to 2.9+ whereas one had the initial mean BI of 1.5+.
  • Also, 2 of the 4 relapsed patients had positive PCR signals at the time of stoppage of treatment.
  • [MeSH-minor] Adenosine Triphosphate / analysis. Adenosine Triphosphate / metabolism. Adolescent. Adult. Animals. Biopsy. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. Female. Follow-Up Studies. Humans. India. Male. Mice. Middle Aged. Polymerase Chain Reaction. RNA, Ribosomal / chemistry. RNA, Ribosomal / genetics. Secondary Prevention. Young Adult

  • Hazardous Substances Data Bank. MINOCYCLINE .
  • Hazardous Substances Data Bank. Ofloxacin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329382.001).
  • [ISSN] 0254-9395
  • [Journal-full-title] Indian journal of leprosy
  • [ISO-abbreviation] Indian J Lepr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / Leprostatic Agents; 0 / RNA, Ribosomal; 8L70Q75FXE / Adenosine Triphosphate; A4P49JAZ9H / Ofloxacin; FYY3R43WGO / Minocycline
  •  go-up   go-down


31. Supe A, Parikh M, Prabhu R, Kantharia C, Farah J: Post-splenectomy response in adult patients with immune thrombocytopenic purpura. Asian J Transfus Sci; 2009 Jan;3(1):6-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-splenectomy response in adult patients with immune thrombocytopenic purpura.
  • AIM: To define response to surgical therapy, pre operative factors influencing outcome and tolerability of surgery in adult patients undergoing splenectomy for ITP.
  • One relapsed patient was detected with accessory spleen and responded after re-surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1997 Jan;121(1):18-22 [9001546.001]
  • [Cites] Ann Surg. 1969 Apr;169(4):616-24 [5813186.001]
  • [Cites] Acta Haematol. 1994;91(1):1-6 [8171929.001]
  • [Cites] Am J Med. 1995 May;98(5):436-42 [7733121.001]
  • [Cites] J Pediatr Surg. 1994 May;29(5):604-8 [8035267.001]
  • [Cites] Br J Surg. 1991 Sep;78(9):1031-8 [1933181.001]
  • [Cites] Arch Dis Child. 1991 Sep;66(9):1070-2 [1929516.001]
  • [Cites] J Pediatr Surg. 1991 Apr;26(4):407-12; discussion 412-3 [2056400.001]
  • [Cites] Br J Haematol. 1990 Oct;76(2):250-5 [2094326.001]
  • [Cites] Blood. 1989 Nov 15;74(7):2309-17 [2478227.001]
  • [Cites] Acta Haematol. 1989;81(1):28-33 [2494831.001]
  • [Cites] N Engl J Med. 1989 Apr 13;320(15):974-80 [2927480.001]
  • [Cites] Ann Surg. 1987 Oct;206(4):529-41 [3662662.001]
  • [Cites] Surg Gynecol Obstet. 1987 Mar;164(3):225-9 [3824112.001]
  • [Cites] World J Surg. 1985 Jun;9(3):422-30 [4040299.001]
  • [Cites] World J Surg. 1985 Jun;9(3):416-21 [4040298.001]
  • [Cites] Arch Dis Child. 1990 Mar;65(3):304-7 [2334210.001]
  • [Cites] Clin Haematol. 1983 Jun;12(2):449-65 [6225588.001]
  • [Cites] Am J Dis Child. 1982 Dec;136(12):1064-6 [6890763.001]
  • [Cites] Arch Surg. 1981 May;116(5):645-50 [7235958.001]
  • [Cites] J Surg Res. 1980 Jan;28(1):14-7 [7359904.001]
  • [Cites] Surg Laparosc Endosc. 1996 Apr;6(2):129-35 [8680635.001]
  • (PMID = 20041089.001).
  • [ISSN] 1998-3565
  • [Journal-full-title] Asian journal of transfusion science
  • [ISO-abbreviation] Asian J Transfus Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2798777
  • [Keywords] NOTNLM ; Idiopathic purpura / surgical therapy
  •  go-up   go-down


32. Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA: Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer; 2006 Jun;52(3):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: The combination of Caelyx, cyclophosphamide and vincristine, despite cyclophosphamide and Caelyx dose reductions, has modest activity in relapsed SCLC with acceptable toxicity.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Male. Middle Aged. Salvage Therapy. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16597474.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


33. Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N: Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas; 2005 Jan;30(1):31-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In group A, 2 patients relapsed in the remnant pancreas.
  • [MeSH-minor] Adult. Aged. Constriction, Pathologic / drug therapy. Constriction, Pathologic / pathology. Constriction, Pathologic / surgery. Edema / drug therapy. Edema / pathology. Edema / surgery. Female. Humans. Male. Middle Aged. Pancreas / pathology. Prognosis. Recurrence. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632697.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


34. Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N: Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma; 2010 Dec;51(12):2222-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.
  • Between 2005 and 2008, we conducted separate phase II clinical testing of three distinct anti-VEGF therapies for patients with relapsed/refractory CLL.
  • Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bevacizumab. Female. Humans. Indoles / administration & dosage. Indoles / adverse effects. Indoles / therapeutic use. Male. Middle Aged. Pyrroles / administration & dosage. Pyrroles / adverse effects. Pyrroles / therapeutic use. Quinazolines / administration & dosage. Quinazolines / adverse effects. Quinazolines / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Leuk Res. 2008 Apr;32(4):593-7 [17928052.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Leuk Lymphoma. 2009 Jan;50(1):62-7 [19125384.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Br J Haematol. 2009 Sep;146(6):660-4 [19604237.001]
  • [Cites] Blood. 2010 Jan 28;115(4):846-9 [19965686.001]
  • [Cites] Blood. 2010 Jun 3;115(22):4447-54 [20164467.001]
  • [Cites] Leuk Lymphoma. 2010 Jul;51(7):1351-3 [20496991.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):353-6 [20182346.001]
  • [Cites] Clin Cancer Res. 2010 Jul 1;16(13):3390-8 [20570929.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):605-10 [10583266.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1414-8 [10942237.001]
  • [Cites] Leuk Res. 2001 Apr;25(4):279-85 [11248324.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):795-9 [11309324.001]
  • [Cites] Leukemia. 2002 May;16(5):911-9 [11986954.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3344-51 [12384436.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):243-8 [14687619.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):965-70 [10070898.001]
  • [Cites] Leukemia. 2005 Apr;19(4):513-23 [15703780.001]
  • [Cites] Leukemia. 2005 Apr;19(4):524-30 [15674425.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4813-9 [15731179.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Leukemia. 2006 Apr;20(4):583-9 [16467866.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):174-85 [16616064.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Leukemia. 2007 Jan;21(1):44-52 [16990761.001]
  • [Cites] Vnitr Lek. 2007 Nov;53(11):1171-6 [18277626.001]
  • (PMID = 21054149.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CM62205; United States / NCI NIH HHS / CM / N01-CM62207; United States / NCI NIH HHS / CM / N01 CM062205; United States / NCI NIH HHS / CA / U24 CA114740; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CM / N01-CM62205; United States / NCI NIH HHS / CA / CA114740; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / N01CM62207; United States / NCI NIH HHS / CA / CA116237; United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CM / N01 CM062207; United States / NCI NIH HHS / CA / R01 CA116237; United States / NCI NIH HHS / CA / N01 CA015083
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / Quinazolines; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; NQU9IPY4K9 / cediranib; V99T50803M / sunitinib
  • [Other-IDs] NLM/ NIHMS550827; NLM/ PMC3928074
  •  go-up   go-down


35. Marisavljević D, Rolović Z, Ludoski-Pantić M, Djordjević V, Novak A: Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients. Med Oncol; 2005;22(4):407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report five adult patients with spontaneous remission of MDS, achieved without cytotoxic or any other treatment.
  • As for the follow-up, none of the patients relapsed.
  • [MeSH-minor] Adult. Aged. Bone Marrow Cells / pathology. Cytogenetic Analysis. Female. Humans. Middle Aged. Remission, Spontaneous


36. Zhang B, Liao J, Wang ZR, Chen Y, Gu JW, Chen LG, Fang J: [Study on short-term therapeutic effect and its impact factors of stereotactic surgery for treating opiate users with opiate dependence in Sichuan]. Wei Sheng Yan Jiu; 2006 Sep;35(5):599-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant decrease of relapse time, relapse dose, subjective feel on drugs and relapse euphoria appeared in patients who relapsed after surgery when compared with those before surgery.
  • A significant decrease of relapse time, relapse dose, subjective feel on drugs and relapse euphoria appeared in patients who relapsed after surgery when compared with those before surgery.
  • [MeSH-minor] Adolescent. Adult. China. Female. Humans. Logistic Models. Male. Middle Aged. Recurrence. Surveys and Questionnaires. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17086714.001).
  • [ISSN] 1000-8020
  • [Journal-full-title] Wei sheng yan jiu = Journal of hygiene research
  • [ISO-abbreviation] Wei Sheng Yan Jiu
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


37. Wang LX, Lu H, Shen WY, Qian SX, Qiu HX, Wu HX, Zhang JF, Wu YJ, Li JY: [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug;16(4):943-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 3 patients with refractory/relapsed myeloma achieved PR (2/3) and MR (1/3).
  • In conclusion, bortezomib demonstrates efficiency in the treatment of new-diagnosed and refractory/relapsed multiple myeloma, and the side effects from treatment are acceptable and manageable.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18718096.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


38. Yamauchi T, Mori Y, Miyamoto T, Kamezaki K, Aoki T, Yamamoto A, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K: Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia. Int J Hematol; 2009 Oct;90(3):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia.
  • Gemtuzumab ozogamicin (GO) is an effective molecular-targeted agent for CD33-positive acute myelogenous leukemia (AML) patients who are resistant to conventional chemotherapy.
  • We report here for the first time three AML cases that relapsed after allogeneic SCT and underwent unrelated cord blood transplantation (UCBT) following reduced-intensity conditioning (RIC) comprising fludarabine, melphalan, and low-dose total body irradiation combined with GO.
  • Notably, one patient who responded to GO survived for 6 months after UCBT in remission with excellent performance status, while the remaining cases relapsed early.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Combined Modality Therapy. Fatal Outcome. Female. Humans. Male. Middle Aged. Recurrence


39. Terwey TH, Massenkeil G, Tamm I, Hemmati PG, Neuburger S, Martus P, Dörken B, Hoelzer D, Arnold R: Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant; 2008 Dec;42(12):791-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.
  • We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy.
  • Leukemia-free survival at 1, 2 and 5 years was 37, 33 and 24%.
  • Deaths were due to relapse (n=25), acute or chronic GVHD (n=7), infections (n=8) or toxicity (n=4).
  • We conclude that patients who undergo HSCT for refractory or relapsed ALL can achieve long-term survival.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Drug Therapy / utilization. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711350.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Bregni M, Bernardi M, Servida P, Pescarollo A, Crocchiolo R, Treppiedi E, Corradini P, Ciceri F, Peccatori J: Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant; 2009 Aug;44(4):237-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transplantation is able to induce long-term disease control in a fraction of relapsed RCC patients.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Prospective Studies. Regression Analysis. Survival Analysis. Transplantation Chimera. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19234510.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


41. Ribi C, Cohen P, Pagnoux C, Mahr A, Arène JP, Lauque D, Puéchal X, Letellier P, Delaval P, Cordier JF, Guillevin L, French Vasculitis Study Group: Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum; 2008 Feb;58(2):586-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 72 patients studied, 93% achieved remission with CS therapy alone, and 35% relapsed, mainly during the first year of treatment.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Disease-Free Survival. Female. Humans. Injections, Intravenous. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. Pulse Therapy, Drug. Recurrence. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Churg-Strauss Syndrome.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240234.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00399399
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; MRK240IY2L / Azathioprine
  •  go-up   go-down


42. Nyman J, Friesland S, Hallqvist A, Seke M, Bergström S, Thaning L, Lödén B, Sederholm C, Wagenius G: How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer; 2009 Jul;65(1):62-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-nine percent of the patients relapsed with distant metastases initially and 31% had loco-regional tumor progression, without significant differences between treatment arms.
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Prognosis. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081652.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


43. Patil S, Spencer A, Schwarer A, Avery S, Ritchie D, Opat S, Wei A, McLean C: Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma; 2009 Dec;50(12):1964-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten patients relapsed after ASCT.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Disease-Free Survival. Female. Germinal Center / drug effects. Germinal Center / pathology. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Severity of Illness Index. Transplantation Conditioning / methods. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860614.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


44. Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA: Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant; 2005 Dec;36(11):955-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all, 44 patients (90%) had relapsed disease and five patients (10%) were resistant to chemotherapy at the time of transplantation.
  • [MeSH-minor] Adult. Age Factors. Aged. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Autologous


45. Zhang DH, Dai M, Zhou HS, Wang YY, Zhang L, Zhang L, Wang B, Cao WJ: [Monitoring CML28 mRNA levels in patients before and after HSCT by real-time quantitative RT-PCR]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct;13(5):843-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to establish a SYBR Green I real-time quantitative RT-PCR method for investigating the correlation between CML28 mRNA expression levels and relapse of leukemia after allo-hematopoietic stem cell transplantation (HSCT).
  • 2 of them with low level (<2 x 10(-2)) survived without relapse, the other 2 case with high level (>2 x 10(-2)) relapsed within one year, 1 case died and 1 case received the second time HSCT, CML28 level decreased rapidly after HSCT, but still higher than 2 x 10(-2) and relapse has taken place.
  • The conclusions was made that CML28 mRNA level is obviously correlated with the development of leukemia.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277855.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / EXOSC5 protein, human; 0 / Organic Chemicals; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 163795-75-3 / SYBR Green I; EC 3.1.- / Exoribonucleases; EC 3.1.- / Exosome Multienzyme Ribonuclease Complex
  •  go-up   go-down


46. Bunin N, Aplenc R, Grupp S, Pierson G, Monos D: Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias. Bone Marrow Transplant; 2006 Jan;37(2):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients relapsed, and 10 patients died of non-relapse causes.
  • [MeSH-major] Antigens, CD3. Antigens, CD34. Leukemia / therapy. Lymphocyte Transfusion. Peripheral Blood Stem Cell Transplantation. Tissue Donors. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chronic Disease. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Disease-Free Survival. Donor Selection / methods. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / administration & dosage. Male. Myeloablative Agonists / administration & dosage. Remission Induction / methods. Thiotepa / administration & dosage. Treatment Outcome. Whole-Body Irradiation / adverse effects. Whole-Body Irradiation / methods. Whole-Body Irradiation / mortality

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284615.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD34; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


47. Abu-Baker NN, Haddad L, Mayyas O: Smoking behavior among coronary heart disease patients in Jordan: a model from a developing country. Int J Environ Res Public Health; 2010 03;7(3):751-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surprisingly, after disease occurrence only 29.7% of the patients quit smoking, while 60.7% continued smoking, and 9.6% relapsed.
  • [MeSH-minor] Adult. Aged. Cross-Sectional Studies. Developing Countries. Female. Humans. Jordan. Male. Middle Aged. Smoking Cessation

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Public Health. 2006 Jan-Feb;97(1):9-13 [16512319.001]
  • [Cites] J Adv Nurs. 2004 Jun;46(6):614-23 [15154902.001]
  • [Cites] CMAJ. 2009 Jun 23;180(13):1297-303 [19546455.001]
  • [Cites] East Mediterr Health J. 2008 Jul-Aug;14(4):897-904 [19166173.001]
  • [Cites] Prog Cardiovasc Nurs. 2008 Spring;23(2):79-83 [18843829.001]
  • [Cites] Eur Heart J. 2006 Jan;27(1):35-41 [16210309.001]
  • [Cites] Public Health Nurs. 2000 Nov-Dec;17(6):460-7 [11115144.001]
  • [Cites] Int J Nurs Stud. 2002 Nov;39(8):793-802 [12379297.001]
  • [Cites] J Epidemiol Community Health. 2000 Sep;54(9):692-6 [10942449.001]
  • [Cites] Am Heart J. 2007 Aug;154(2):213-20 [17643569.001]
  • [Cites] Circulation. 1996 Jan 1;93(1):42-7 [8616939.001]
  • [Cites] Arch Intern Med. 2008 Oct 13;168(18):1950-60 [18852395.001]
  • [Cites] Int J Cardiol. 2005 Apr 20;100(2):241-5 [15823631.001]
  • [Cites] Circ J. 2005 Jan;69(1):7-12 [15635194.001]
  • [Cites] J Nurs Res. 2008 Mar;16(1):55-64 [18348108.001]
  • [Cites] Milbank Q. 2002;80(3):433-79, iii [12233246.001]
  • [Cites] Am J Prev Med. 2004 Dec;27(5):411-6 [15556742.001]
  • [Cites] Tob Control. 2002 Jun;11(2):119-24 [12035004.001]
  • [Cites] Environ Health Prev Med. 2002 May;7(2):74-8 [21432267.001]
  • [Cites] Int Q Community Health Educ. 2006-2007;26(4):397-413 [17890184.001]
  • [Cites] Ann Epidemiol. 2002 Jul;12(5):316-20 [12062918.001]
  • [Cites] J Clin Epidemiol. 2006 Jun;59(6):622-8 [16713525.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):86-97 [12837716.001]
  • [Cites] BMJ. 2001 Oct 27;323(7319):957-62 [11679383.001]
  • (PMID = 20617001.001).
  • [ISSN] 1660-4601
  • [Journal-full-title] International journal of environmental research and public health
  • [ISO-abbreviation] Int J Environ Res Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC2872319
  • [Keywords] NOTNLM ; Jordan (major topic) / coronary heart disease (major topic) / persistent smoker (major topic) / quitter smoker (major topic) / smoking cessation (major topic)
  •  go-up   go-down


48. Oechsle K, Bokemeyer C, Honecker F: Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol; 2010 Jan;136(1):165-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
  • OBJECTIVE: Treatment options are still limited in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
  • PATIENTS AND METHODS: Four patients multiply relapsed after platin-based chemotherapies without any further standard treatment option received 25 mg lenalidomide orally on days 1-21 of a 28-day cycle.
  • CONCLUSION: Lenalidomide was well tolerated but did not show efficacy in heavily pretreated patients with cisplatin-refractory and multiply relapsed germ cell tumors.
  • [MeSH-minor] Adult. Cisplatin / therapeutic use. Compassionate Use Trials. Drug Resistance, Neoplasm. Humans. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Cancer Res Clin Oncol. 2010 Jan;136(1):169
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1777-81 [1700077.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2031-7 [11956262.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):512-6 [10080593.001]
  • [Cites] Drugs. 1999 Aug;58(2):257-81 [10473019.001]
  • [Cites] Ann Oncol. 1996 Jan;7(1):31-4 [9081388.001]
  • [Cites] Semin Oncol. 1990 Feb;17(1 Suppl 2):36-9 [2154858.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1775-9 [16765039.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):509-11 [10080592.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):161-8 [8988741.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1295 [15277272.001]
  • (PMID = 19760194.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL: Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. Eur J Nucl Med Mol Imaging; 2005 Oct;32(10):1225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Nine patients with relapsed, refractory or transformed B-NHL received ten radioimmunotherapies.
  • RESULTS: No acute adverse effects were observed after the administration of 131I-rituximab.
  • Of two patients who received radioimmunotherapy as an additional treatment after salvage chemotherapy, one continues to be disease-free at 9 months and one relapsed at 5 months' follow-up.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Pilot Projects. Radiation Injuries / etiology. Radiopharmaceuticals / adverse effects. Radiopharmaceuticals / therapeutic use. Severity of Illness Index. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1263-70 [12663713.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Cancer Pract. 1998 May-Jun;6(3):195-7 [9652253.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1363-72 [11877767.001]
  • [Cites] Clin Immunol. 2001 Jul;100(1):40-8 [11414744.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):58-65 [10561019.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1259-66 [10942366.001]
  • [Cites] Nuklearmedizin. 2002 Apr;41(2):71-9 [11989301.001]
  • [Cites] Lancet. 1995 Aug 5;346(8971):336-40 [7623531.001]
  • [Cites] J Nucl Med. 1990 Jan;31(1):84-9 [2295945.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1023-30 [8450856.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3281s-3286s [10541376.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Oct;29(10 ):1276-82 [12271407.001]
  • [Cites] J Clin Oncol. 1996 Jul;14 (7):1974-81 [8683227.001]
  • [Cites] J Nucl Med. 1998 Aug;39(8 Suppl):21S-27S [9708567.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3246-56 [9779698.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):341-53 [15172354.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Aug;18(4):513-24 [14503945.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3304s-3314s [10541379.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1219-24 [7692295.001]
  • [Cites] Cancer Immunol Immunother. 2003 May;52(5):281-96 [12700944.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Eur J Nucl Med. 2000 Jul;27(7):766-77 [10952488.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10 ):3270-8 [9779701.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1027-38 [2666588.001]
  • [Cites] Eur J Haematol. 2004 Jan;72(1):10-7 [14962257.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Clin Oncol. 1992 Nov;10 (11):1696-711 [1403053.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 15937686.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 131I-rituximab; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Radiopharmaceuticals
  •  go-up   go-down


50. Proctor SJ, Chapman CE, Sharples R, Lucraft HL, Wilkinson J, Conn J, Middleton PG: Enhanced engraftment of a very low-dose cord blood unit in an adult haemopoietic transplant by addition of six mismatched viable cord units. Stem Cells Int; 2010;2010:431909
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced engraftment of a very low-dose cord blood unit in an adult haemopoietic transplant by addition of six mismatched viable cord units.
  • An ablative stem cell transplant was performed in an adult with relapsed acute lymphoblastic leukaemia (ALL), using a single HLA-matched cord blood unit (mononuclear cell dose 0.8 × 10(7)), supported by six mismatched cord blood units (one unit per 10 kg recipient weight).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048848.001).
  • [ISSN] 1687-9678
  • [Journal-full-title] Stem cells international
  • [ISO-abbreviation] Stem Cells Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2956468
  •  go-up   go-down


51. Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R: Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol; 2006 Nov;1(6):1173-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients stayed in remission during the post-MMF period, for periods of 18 to 30 mo, whereas 16 relapsed after stopping MMF.
  • Eight (25%) of 32 patients relapsed while taking MMF.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Drug Administration Schedule. Humans. Monitoring, Physiologic. Patient Selection. Proteinuria. Recurrence

  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699344.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


52. Mert A, Kumbasar H, Ozaras R, Erten S, Tasli L, Tabak F, Ozturk R: Erythema nodosum: an evaluation of 100 cases. Clin Exp Rheumatol; 2007 Jul-Aug;25(4):563-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nodosities relapsed annually in 62% (33/53) of idiopathic EN patients but in only one (BS) in the secondary EN group.
  • [MeSH-minor] Adolescent. Adult. Biopsy. Female. Humans. Male. Middle Aged. Prospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17888212.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Narayana Y, Joshi B, Katoch VM, Mishra KC, Balaji KN: Differential B-cell responses are induced by Mycobacterium tuberculosis PE antigens Rv1169c, Rv0978c, and Rv1818c. Clin Vaccine Immunol; 2007 Oct;14(10):1334-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study population (n = 211) was comprised of different clinical groups of both adult and child patients: group 1 (n = 94) patients with pulmonary infection, group 2 (n = 30) patients with relapsed infection, group 3 (n = 31) patients with extrapulmonary infections, and clinically healthy donors (n = 56).
  • Among the PE proteins studied, group 1 adult patient sera reacted to Rv1818c and Rv0978c, while Rv1169c elicited immunoreactivity in group 3 children.
  • However, all three PE antigens studied as well as the 19-kDa antigen did not demonstrate humoral reactivity with sera from group 2 patients with relapsed infection.
  • The current study shows that while responsiveness to all three PE antigens is a good marker for M. tuberculosis infection, a strong response to Rv0978c or to Rv1818c by group 1 adult patients with pulmonary infection or largely restricted reactivity to Rv1169c antigen in child patients with extrapulmonary infections offers the possibility of differential utility in the serodiagnosis of tuberculosis.
  • [MeSH-minor] Adolescent. Adult. Antibodies, Bacterial / biosynthesis. Child. Child, Preschool. Humans. Middle Aged

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 2001 Sep;69(9):5606-11 [11500435.001]
  • [Cites] J Immunol. 2001 Jul 15;167(2):910-8 [11441098.001]
  • [Cites] Mol Microbiol. 2002 Apr;44(1):9-19 [11967065.001]
  • [Cites] Trends Microbiol. 2002 May;10(5):246-9 [11973159.001]
  • [Cites] J Immunol. 2003 Jan 1;170(1):430-7 [12496428.001]
  • [Cites] J Biosci. 2003 Mar;28(2):169-79 [12711809.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7213-8 [12775759.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):175-84 [12816996.001]
  • [Cites] J Exp Med. 2003 Sep 1;198(5):693-704 [12953091.001]
  • [Cites] Infect Immun. 2003 Nov;71(11):6338-43 [14573653.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4602-7 [15070764.001]
  • [Cites] Mol Microbiol. 2004 May;52(3):725-33 [15101979.001]
  • [Cites] Tuberculosis (Edinb). 2004;84(3-4):256-62 [15207495.001]
  • [Cites] J Infect Dis. 2004 Oct 1;190(7):1237-44 [15346333.001]
  • [Cites] Comput Appl Biosci. 1988 Mar;4(1):181-6 [2454713.001]
  • [Cites] Bull Int Union Tuberc Lung Dis. 1990 Mar;65(1):6-24 [2190653.001]
  • [Cites] Infect Immun. 1991 Aug;59(8):2712-8 [1830294.001]
  • [Cites] J Immunol. 1991 Oct 15;147(8):2706-12 [1717575.001]
  • [Cites] Immunology. 1991 Sep;74(1):1-7 [1718849.001]
  • [Cites] Nature. 1998 Jun 11;393(6685):537-44 [9634230.001]
  • [Cites] Infect Immun. 1998 Aug;66(8):3936-40 [9673283.001]
  • [Cites] Mol Microbiol. 1999 Mar;31(6):1603-9 [10209735.001]
  • [Cites] Science. 1999 Jul 30;285(5428):732-6 [10426995.001]
  • [Cites] Infect Immun. 2006 Feb;74(2):1233-42 [16428773.001]
  • [Cites] Microbes Infect. 2006 Jan;8(1):262-72 [16203168.001]
  • [Cites] J Infect Dis. 2006 May 1;193(9):1287-95 [16586367.001]
  • [Cites] Microbiology. 1999 Dec;145 ( Pt 12):3487-95 [10627046.001]
  • [Cites] Science. 2000 May 26;288(5470):1436-9 [10827956.001]
  • [Cites] Nat Med. 2000 Dec;6(12):1327-9 [11100115.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):447-57 [11123323.001]
  • [Cites] Infect Immun. 2001 Jun;69(6):4185-91 [11349098.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7326-33 [11705904.001]
  • (PMID = 17687113.001).
  • [ISSN] 1556-6811
  • [Journal-full-title] Clinical and vaccine immunology : CVI
  • [ISO-abbreviation] Clin. Vaccine Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 144058-44-6 / Mycobacterium tuberculosis antigens
  • [Other-IDs] NLM/ PMC2168116
  •  go-up   go-down


54. Mego M, Rejlekova K, Reckova M, Sycova-Mila Z, Obertova J, Rajec J, Mardiak J: Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors. Neoplasma; 2009;56(5):398-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.
  • The aim of the study was to assess the prognostic value of STMD in relapsed GCT;s patients.
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Humans. Kinetics. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Testicular Neoplasms / blood. Testicular Neoplasms / mortality. Testicular Neoplasms / pathology. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19580341.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


55. Ottmann OG, Wassmann B: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2005;:118-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL.
  • Until recently, conventional chemotherapy programs that have been effective in other precursor B-cell ALL cases have been unable to cure patients with this diagnosis.
  • The results from clinical trials using imatinib in the frontline setting and in relapsed patients as well as preliminary experience treating imatinib-resistant Ph(+) ALL will be described.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304368.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; VB0R961HZT / Prednisone
  •  go-up   go-down


56. Takaku Y, Nakagome K, Kobayashi T, Yamaguchi T, Nishihara F, Soma T, Hagiwara K, Kanazawa M, Nagata M: Changes in airway inflammation and hyperresponsiveness after inhaled corticosteroid cessation in allergic asthma. Int Arch Allergy Immunol; 2010;152 Suppl 1:41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study evaluates changes in airway inflammation and hyperresponsiveness in adult patients with asthma after stopping ICS.
  • RESULTS: Among the 11 asthmatics, AHR increased in 10 (90.9%) and asthma clinically relapsed in 4 (36.4%) within 1 year of ICS cessation.
  • AHR increased in all 7 asthmatics that were sensitized to Dermatophagoides farinae and asthma clinically relapsed in 4 (57.1%) of them.
  • CONCLUSIONS: Remission with normal airway response to methacholine (no AHR) might be rare in adult patients with allergic asthma, and sensitization to house dust mites appears to play an important role in relapse.
  • [MeSH-minor] Adult. Aged. Antigens, Dermatophagoides / immunology. Eosinophils / cytology. Female. Follow-Up Studies. Forced Expiratory Volume / physiology. Humans. Immunoglobulin E / blood. Immunoglobulin E / immunology. Inflammation / metabolism. Inflammation / pathology. Interferon-gamma / metabolism. Interleukin-4 / metabolism. Leukocyte Count. Male. Middle Aged. Recurrence. Sputum / cytology. Sputum / metabolism

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 S. Karger AG, Basel.
  • (PMID = 20523062.001).
  • [ISSN] 1423-0097
  • [Journal-full-title] International archives of allergy and immunology
  • [ISO-abbreviation] Int. Arch. Allergy Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antigens, Dermatophagoides; 0 / IL4 protein, human; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


57. Healy E, Newell L, Howarth P, Friedmann PS: Control of salicylate intolerance with fish oils. Br J Dermatol; 2008 Dec;159(6):1368-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Symptoms relapsed after dose reduction.
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795922.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Fish Oils; O414PZ4LPZ / Salicylic Acid
  •  go-up   go-down


58. Fotopoulou C, Savvatis K, Braicu EI, Brink-Spalink V, Darb-Esfahani S, Lichtenegger W, Sehouli J: Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome. Gynecol Oncol; 2010 Nov;119(2):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome.
  • Aim of the present study was to describe surgical and clinical outcome and dissemination pathways in the primary and recurrent situation of the disease.
  • METHODS: All primary and relapsed GCT-patients, operated between 01/2001 and 02/2010 in our institution were evaluated using a systematic intraoperative documentation-tool (IMO).
  • Surgical outcome, intraoperative tumor-dissemination-pattern and pathological and findings were separately analyzed for the primary and recurrent situation.
  • RESULTS: Overall, 45 patients were analyzed; including eighteen patients with primary and 27 patients with recurrent GCT.
  • Tumor-dissemination-patterns differed significantly between primary and recurrent patients, by the latter having significantly higher rates of diffuse peritoneal involvement (15.8% vs. 52%; p=0.027) and of extraovarian tumor involvement of the middle (15.8% vs. 48.1%; p=0.05) and upper abdomen (0 vs. 33.3%; p=0.006).
  • While all primary patients could be operated tumor-free, this was the case for 85.2% of the relapsed patients (p=0.13).
  • A multivisceral operative approach with extensive peritonectomy, intestinal or diaphragmatic resection, splenectomy and partial hepatectomy/panceratectomy had to be performed only in recurrent GCT (55.6%).
  • CONCLUSIONS: Tumor-dissemination-pathways followed in primary and recurrent GCT differ significantly by higher rates of multivisceral tumor involvement in the recurrent situation of the disease.
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20637497.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S: Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res; 2009 Aug 15;15(16):5250-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
  • EXPERIMENTAL DESIGN: A phase I trial evaluated sequential dose escalation of bortezomib at 1 to 1.3 mg/m2 i.v. on days 1, 4, 8, and 11 and vorinostat at 100 to 500 mg orally daily for 8 days of each 21-day cycle in relapsed/refractory multiple myeloma patients.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Sep 7;19(38):4319-27 [10980607.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2917-26 [18641367.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5673-83 [12173037.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Oncogene. 2003 Apr 24;22(16):2417-21 [12717418.001]
  • [Cites] Blood. 2003 May 15;101(10):4055-62 [12531799.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3637-45 [12839953.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2615-22 [12816865.001]
  • [Cites] Cell. 2003 Dec 12;115(6):727-38 [14675537.001]
  • [Cites] Nat Rev Drug Discov. 2004 Jan;3(1):17-26 [14708018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5 [14695887.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3839-52 [15173093.001]
  • [Cites] Mayo Clin Proc. 2004 Jul;79(7):867-74 [15244382.001]
  • [Cites] J Pharmacokinet Biopharm. 1978 Feb;6(1):79-98 [650423.001]
  • [Cites] Comput Programs Biomed. 1983 Jun;16(3):203-16 [6688572.001]
  • [Cites] Cell Death Differ. 1998 Dec;5(12):1062-75 [9894613.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(23):10161-8 [15542827.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8 [15637150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3697-702 [15738394.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):686-92 [15827343.001]
  • [Cites] Exp Cell Res. 2005 Jul 1;307(1):15-25 [15922723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72 [15937109.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4589-600 [15958645.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4089-99 [15867202.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5429-44 [15964800.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11658-66 [16357177.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3773-81 [16585204.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3997-4003 [16818698.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Aug 18;840(2):108-15 [16725386.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4628-35 [16899611.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3441-9 [16728695.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):219-25 [17477906.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3605-10 [17510206.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3362-71 [17664484.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):332-3; discussion 333-4 [18182676.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1060-6 [17962510.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):502-7 [18297527.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Oncol. 2008 May;19(5):964-9 [18296419.001]
  • [Cites] Mol Cancer Res. 2008 Aug;6(8):1356-64 [18708367.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2439-49 [18614762.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):194-202 [11902574.001]
  • (PMID = 19671864.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR016500-078185; United States / NCRR NIH HHS / RR / RR016500-066172; United States / NCI NIH HHS / CA / CA93783; United States / NCRR NIH HHS / RR / M01-RR00071; United States / NCI NIH HHS / CA / R01 CA100866; United States / NCRR NIH HHS / RR / M01 RR000071; United States / NCI NIH HHS / CO / N01-CO-124001; United States / NCI NIH HHS / CA / R01 CA093738; United States / NCI NIH HHS / CA / CA 100866; United States / NCRR NIH HHS / RR / M01 RR016500-066172; United States / NCRR NIH HHS / RR / M01 RR016500-078185
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Hydroxamic Acids; 0 / Pyrazines; 58IFB293JI / vorinostat; 69G8BD63PP / Bortezomib
  • [Other-IDs] NLM/ NIHMS129692; NLM/ PMC2758911
  •  go-up   go-down


60. Tsao TC, Chen CH, Chang JW, Lee CH: Weekly short infusion of taxotere at a 4 week cycle in Chinese patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based non-taxane chemotherapy--a Phase II trial. Jpn J Clin Oncol; 2006 Feb;36(2):80-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly short infusion of taxotere at a 4 week cycle in Chinese patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based non-taxane chemotherapy--a Phase II trial.
  • BACKGROUND: This Phase II study was conducted to evaluate the efficacy and toxicity of weekly docetaxel at a 4 week cycle in second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) who failed to respond or relapsed after the frontline platinum-based, non-taxane regimen.
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455677.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


61. Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhommé C: Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol; 2010 Feb;116(2):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Women (>18 years) with platinum-resistant/refractory (relapsed<6 months), or platinum-sensitive (relapsed >6 months) disease after first-line platinum-based and P chemotherapy.
  • Two secondary myelodysplastic syndromes (MDS) and one secondary acute leukemia occurred during treatment, and one MDS 34 months after treatment discontinuation.
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Quinazolines / administration & dosage. Quinazolines / adverse effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20109725.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; S65743JHBS / gefitinib
  •  go-up   go-down


62. Vaccher E, di Gennaro G, Simonelli C, Schioppa O, Tirelli U, Italian Cooperative Group on AIDS, Tumors (GICAT): Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. AIDS; 2005 Nov 4;19(16):1915-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were relapsed/progressed during highly active antiretroviral therapy, administered as primary antineoplastic therapy.
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227802.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


63. Kan Y, Yao P, Xin W, Chen Q, Wang J, Yue J, Zhu J: [Recent progress on diagnosis and treatment of benign symmetric lipomatosis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Feb;24(3):105-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During a follow-up of 3 months to 4 years, one patients was relapsed again, and no recurrence was seen in another 4 patients.
  • [MeSH-minor] Adult. Alcoholism / complications. Fascia / pathology. Female. Humans. Lipectomy. Male. Middle Aged. Neck / pathology. Shoulder / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429378.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Benign symmetrical lipomatosis
  •  go-up   go-down


64. Tamada RS, Amaral JA, Issler CK, Nierenberg AA, Lafer B: Antidepressant treatment-emergent affective switch in bipolar disorder: a prospective case-control study of outcome. Rev Bras Psiquiatr; 2006 Dec;28(4):297-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with treatment-emergent affective switch relapsed in a shorter period than patients with spontaneous mania (p = 0.016).
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Cyclothymic Disorder / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Psychiatric Status Rating Scales. Recurrence. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Bras Psiquiatr. 2007 Mar;29(1):86-7; author reply 87-8 [17435935.001]
  • (PMID = 17242809.001).
  • [ISSN] 1516-4446
  • [Journal-full-title] Revista brasileira de psiquiatria (São Paulo, Brazil : 1999)
  • [ISO-abbreviation] Rev Bras Psiquiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antidepressive Agents
  •  go-up   go-down


65. Kane A, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P: Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary. Fertil Steril; 2010 Dec;94(7):2891-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients relapsed (three with an invasive recurrence), but none of the patients without residual disease at the end of surgery, or invasive implants or disease with a micropapillary pattern relapsed under the form of invasive carcinoma.
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Feasibility Studies. Female. Follow-Up Studies. Gynecologic Surgical Procedures / methods. Gynecologic Surgical Procedures / rehabilitation. Humans. Infertility, Female / rehabilitation. Infertility, Female / surgery. Middle Aged. Neoplasm Staging. Pregnancy. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20537629.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D, Andresen S, Kuczkowski E, Bolwell B: CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant; 2005 Feb;35(3):247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD.
  • Although 67% of evaluable patients developed acute GVHD, severe grade III-IV acute GVHD only developed in 19%.
  • The severity of acute GVHD correlated with the degree of CD8+ TCD.
  • [MeSH-major] Bone Marrow Transplantation / methods. Busulfan / administration & dosage. CD8-Positive T-Lymphocytes. Leukemia, Myeloid, Acute / therapy. Lymphocyte Depletion / methods
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Female. Graft Survival. Graft vs Host Disease / prevention & control. Histocompatibility. Histocompatibility Testing. Humans. Male. Middle Aged. Salvage Therapy / methods. Survival Analysis. Tissue Donors. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15580282.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan; U68WG3173Y / Carmustine; CBV protocol
  •  go-up   go-down


67. Lindberg A, Eberhardson M, Karlsson M, Karlén P: Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol; 2010;10:73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Relapsed patients were re-treated by GMA in this follow-up study up to 58 months.
  • Fourteen patients who relapsed after showing initial remission were re-treated with GMA and 13 (93%) went into a second remission.
  • [MeSH-minor] Adolescent. Adult. Chronic Disease. Colitis, Ulcerative / blood. Colitis, Ulcerative / therapy. Female. Follow-Up Studies. Humans. Longitudinal Studies. Male. Middle Aged. Quality of Life. Remission Induction. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):878-83 [10201450.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(4):CD000301 [14583917.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Dec;20(11-12):1347-52 [15606397.001]
  • [Cites] J Gastroenterol. 2004 Dec;39(12):1158-64 [15622479.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):93-101 [15654787.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1805-11 [15940615.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):819-26 [16143121.001]
  • [Cites] J Clin Apher. 2005 Oct;20(3):171-84 [15892107.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2462-76 [16339095.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):75-81 [16440421.001]
  • [Cites] Inflamm Bowel Dis. 2006 Jul;12(7):641-50 [16804402.001]
  • [Cites] Inflamm Bowel Dis. 2000 Feb;6(1):21-33 [10701146.001]
  • [Cites] Dig Dis Sci. 2006 Sep;51(9):1525-31 [16902810.001]
  • [Cites] Scand J Gastroenterol. 2006 Oct;41(10):1196-203 [16990205.001]
  • [Cites] Nat Med. 2007 Jan;13(1):26-8 [17206128.001]
  • [Cites] Dig Liver Dis. 2007 May;39(5):430-4 [17379588.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):3097-106 [17853946.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1430-8 [18054751.001]
  • [Cites] Transfus Apher Sci. 2007 Oct;37(2):191-200 [17974479.001]
  • [Cites] Inflamm Bowel Dis. 2008 Jan;14(1):47-52 [17828783.001]
  • [Cites] World J Gastroenterol. 2008 Jan 21;14(3):354-77 [18200659.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):929-36 [18294633.001]
  • [Cites] Gastroenterology. 2008 Aug;135(2):400-9 [18602921.001]
  • [Cites] Inflamm Bowel Dis. 2008 Oct;14(10):1413-8 [18521900.001]
  • [Cites] Inflamm Bowel Dis. 2008 Nov;14(11):1575-84 [18512245.001]
  • [Cites] Scand J Gastroenterol. 2009;44(4):431-40 [19101844.001]
  • [Cites] Dig Dis Sci. 2010 May;55(5):1421-8 [19517236.001]
  • [Cites] J Clin Gastroenterol. 2006 Jul;40(6):482-9 [16825929.001]
  • [Cites] Inflamm Bowel Dis. 2000 Feb;6(1):48-57; discussion 58 [10701150.001]
  • [Cites] Annu Rev Med. 2000;51:289-98 [10774465.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3469-77 [11151879.001]
  • [Cites] J Clin Apher. 2001;16(1):1-9 [11309823.001]
  • [Cites] Gastroenterol Clin North Am. 2001 Mar;30(1):223-41 [11394032.001]
  • [Cites] Am J Gastroenterol. 2001 Aug;96(8):2373-81 [11513177.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1098-104 [11596589.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2915-20 [11693326.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):402-13 [14762776.001]
  • [Cites] Gastroenterology. 2004 May;126(6):1582-92 [15168369.001]
  • [Cites] Digestion. 2004;70(1):36-44 [15297776.001]
  • [Cites] Lancet. 1980 Mar 8;1(8167):514 [6102236.001]
  • [Cites] Gastroenterology. 1987 Jun;92(6):1894-8 [3569765.001]
  • [Cites] Clin Exp Immunol. 1991 Dec;86(3):489-93 [1684141.001]
  • [Cites] Immunol Today. 1995 Jan;16(1):21-6 [7880385.001]
  • [Cites] Gut. 1998 Apr;42(4):470-6 [9616306.001]
  • [Cites] Lancet. 1999 Feb 6;353(9151):459-61 [9989717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):351-8 [11773639.001]
  • [Cites] Dig Dis Sci. 2002 Jun;47(6):1334-41 [12064810.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • [Cites] Gut. 2003 Jul;52(7):998-1002 [12801957.001]
  • [Cites] Ther Apher Dial. 2003 Feb;7(1):48-59 [12921115.001]
  • [Cites] Curr Opin Immunol. 1999 Aug;11(4):392-9 [10448137.001]
  • (PMID = 20604939.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2914086
  •  go-up   go-down


68. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ: Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res; 2007 Oct 15;13(20):6168-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Patients with relapsed/refractory CD20+ B cell non-Hodgkin's lymphoma received i.v. rituximab (375 mg/m2/week for 4 weeks) and PF-3512676 weekly for 4 weeks either i.v. (0.04, 0.16, 0.32, or 0.48 mg/kg) or s.c. (0.01, 0.04, 0.08, or 0.16 mg/kg).
  • CONCLUSION: Brief or extended-duration PF-3512676 can be safely administered in combination with rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Cohort Studies. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947483.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


69. Gatcombe HG, Marcus RB Jr, Katzenstein HM, Tighiouart M, Esiashvili N: Excellent local control from radiation therapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven patients relapsed, all distantly.
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / mortality. Abdominal Neoplasms / radiotherapy. Abdominal Neoplasms / surgery. Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Female. Gene Amplification. Genes, myc / genetics. Humans. Infant. Male. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / mortality. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / surgery. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Risk. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / mortality. Thoracic Neoplasms / radiotherapy. Thoracic Neoplasms / surgery. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211198.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Osman K, Elliott B, Mandeli J, Scigliano E, Malone A, Isola L, Grosskreutz C: Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. Am J Hematol; 2010 Apr;85(4):249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results are encouraging when used during first remission in low-risk patients, but less-so in relapsed or refractory disease.
  • These data suggest a benefit of NST in relapsed/refractory MM.
  • [MeSH-minor] Adult. Aged. Aging. Antilymphocyte Serum / therapeutic use. Cohort Studies. Female. Humans. Immunosuppressive Agents / therapeutic use. Kaplan-Meier Estimate. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Recurrence. Retrospective Studies. Transplantation, Homologous. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Whole-Body Irradiation. beta 2-Microglobulin / blood

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162541.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; 0 / beta 2-Microglobulin; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


71. Matondo M, Bousquet-Dubouch MP, Gallay N, Uttenweiler-Joseph S, Recher C, Payrastre B, Manenti S, Monsarrat B, Burlet-Schiltz O: Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Leuk Res; 2010 Apr;34(4):498-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
  • The proteasome inhibitor bortezomib has recently been approved for the treatment of relapsed and refractory multiple myeloma.
  • In this study, we investigated the induction of apoptosis by proteasome inhibitors in several human acute myeloid leukemia (AML) cell lines and in primary cells from patients.
  • [MeSH-major] Apoptosis / drug effects. Leukemia, Myeloid, Acute / pathology. Protease Inhibitors / pharmacology. Proteasome Endopeptidase Complex / metabolism. Proteasome Inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacology. Boronic Acids / pharmacology. Bortezomib. Daunorubicin / pharmacology. Drug Resistance, Neoplasm / drug effects. Drug Resistance, Neoplasm / physiology. Female. HL-60 Cells. Humans. Leupeptins / pharmacology. Male. Middle Aged. Prognosis. Pyrazines / pharmacology. Tumor Cells, Cultured. U937 Cells

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • [CommentIn] Leuk Res. 2010 Apr;34(4):411-2 [19819547.001]
  • (PMID = 19811823.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Leupeptins; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


72. Bravi I, Nicita MT, Duca P, Grigolon A, Cantù P, Caparello C, Penagini R: A pneumatic dilation strategy in achalasia: prospective outcome and effects on oesophageal motor function in the long term. Aliment Pharmacol Ther; 2010 Mar;31(6):658-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve of the 69 patients relapsed after 2.6 years (1.7-5.1): nine of 12 underwent one to two further dilations.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Achalasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20003094.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A: Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant; 2008 Feb;41(4):355-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only three patients relapsed; cumulative incidence 25%.
  • NRM was 42%, predominantly due to acute GVHD.
  • Zevalin-RIC is feasible with consistent engraftment, acceptable organ toxicity, but high rates of acute GVHD.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radioimmunotherapy / methods. Remission Induction. Transplantation, Homologous. omega-Conotoxin GVIA

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026153.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Myeloablative Agonists; 0 / ibritumomab tiuxetan; 92078-76-7 / omega-Conotoxin GVIA
  •  go-up   go-down


74. Wang W, Zhang M, Zhan X, Wang W, Jiang T: [Surgical treatment for maxillary sinus benign diseases under nasal endoscopy]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Jul;22(14):645-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULT: All patients were followed up for a period of more than 6 months, 39 cases were cured (95.1%), 2 cases relapsed.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Paranasal Sinus Diseases / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841795.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


75. Tsai MJ, Liao KS, Shih PM, Lee KT, Chuang WL, Chiu YJ, Lin ZY: Relapsed acute pancreatitis as the initial presentation of pancreatic cancer in a young man: a case report. Kaohsiung J Med Sci; 2010 Aug;26(8):448-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed acute pancreatitis as the initial presentation of pancreatic cancer in a young man: a case report.
  • In this report, we describe a 31-year-old man in whom acute pancreatitis was the initial feature of a subsequently diagnosed pancreatic adenocarcinoma with multiple metastases.
  • He initially presented at our hospital with acute pancreatitis.
  • Four months later, he returned to our hospital with relapsed acute pancreatitis.
  • To our knowledge, this is the youngest case of pancreatic cancer with the uncommon initial presentation of acute pancreatitis reported in the literature.
  • For a patient with acute pancreatitis, particularly recurrent episodes, but with no known risk factors for pancreatitis, a pancreatic neoplasm should be considered as a potential underlying cause, even in a young man.
  • [MeSH-minor] Acute Disease / therapy. Adult. Fatal Outcome. Humans. Male. Recurrence

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20705257.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


76. Meleshko AN, Belevtsev MV, Savitskaja TV, Potapnev MP: The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression. Leuk Res; 2006 Jul;30(7):795-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression.
  • Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangement is conventionally used for assessment of lymphoid malignant cells.
  • TCR genes rearrangements were reported to occur at high frequency in B-lineage acute lymphoblastic leukemia (ALL).
  • Therefore, we have analyzed 83 children with acute B-lineage ALL (67 de novo patients and 19 relapses) by PCR analysis for clonal IgH, incomplete TCRD (Vdelta2-Ddelta3 and Ddelta2-Ddelta3) and TCRG rearrangements.
  • That was equally detected both in de novo and relapsed cases of disease.
  • [MeSH-major] Burkitt Lymphoma / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Immunophenotyping. Infant. Male. Polymerase Chain Reaction / methods. Recurrence. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386788.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / TEL-AML1 fusion protein; 146150-85-8 / E2A-Pbx1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


77. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E: Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology; 2010 Sep;52(3):822-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Part 1 evaluated single-agent pegylated interferon lambda (PEG-IFN-lambda) at 1.5 or 3.0 microg/kg administered every 2 weeks or weekly for 4 weeks in patients who had relapsed after previous IFN-alpha-based treatment.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Dose-Response Relationship, Drug. Drug Therapy, Combination. Fatigue / chemically induced. Female. Genotype. Humans. Male. Middle Aged. Nausea / chemically induced. Polyethylene Glycols / adverse effects. Polyethylene Glycols / therapeutic use. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20564352.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / IL29 protein, human; 0 / Interleukins; 0 / Recombinant Proteins; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin
  •  go-up   go-down


78. Shimokawa T, Kojima Y: [Reinduction therapy with gemtuzumab ozogamicin for relapsed or refractory CD33-positive acute myelogeneous leukemia]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1427-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reinduction therapy with gemtuzumab ozogamicin for relapsed or refractory CD33-positive acute myelogeneous leukemia].
  • The efficacy and safety of reinduction therapy with gemtuzumab ozogamicin (GO)were investigated in 7 patients with relapsed or refractory CD33-positive acute myelogeneous leukemia.
  • [MeSH-major] Aminoglycosides / immunology. Aminoglycosides / therapeutic use. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / immunology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Female. Humans. Immunotherapy. Male. Middle Aged. Recurrence. Sialic Acid Binding Ig-like Lectin 3. Treatment Failure

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701865.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  •  go-up   go-down


79. Yoshimitsu M, Fujiwara H, Ozaki A, Hamada H, Matsushita K, Arima N, Tei C: Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol; 2008 Oct;88(3):331-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.
  • A 23-year-old man with Philadelphia-chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his HLA-identical brother in first hematological remission following induction chemotherapy which included imatinib.
  • He had no acute graft-versus-host disease (GVHD), and 4.5 months after HSCT, he had a molecular relapse (180,000 copies/mug RNA of minor bcr/abl transcripts (m-bcr/abl) without mutation in 22 sites including the p-loop region).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Living Donors. Lymphocyte Transfusion. Philadelphia Chromosome. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Cyclosporine / administration & dosage. Humans. Imatinib Mesylate. Male. Remission Induction. Siblings. Transplantation, Homologous


80. Kuncio D, Maganzini A, Shelton C, Freeman K: Invisalign and traditional orthodontic treatment postretention outcomes compared using the American Board of Orthodontics objective grading system. Angle Orthod; 2007 Sep;77(5):864-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: In this sample for this period of observation, patients treated with Invisalign relapsed more than those treated with conventional fixed appliances.
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Male. Orthodontic Brackets. Orthodontic Retainers / utilization. Orthodontics. Recurrence. Reproducibility of Results. Specialty Boards. Statistics, Nonparametric. Time Factors. Treatment Outcome. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17685783.001).
  • [ISSN] 0003-3219
  • [Journal-full-title] The Angle orthodontist
  • [ISO-abbreviation] Angle Orthod
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Schwinger W, Klass V, Benesch M, Lackner H, Dornbusch HJ, Sovinz P, Moser A, Schwantzer G, Urban C: Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol; 2005 Jul;16(7):1199-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: IL-2 treatment in children with refractory and relapsed solid malignancies is associated with severe, but reversible, side-effects.


82. Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM: Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther; 2010;12(6):R208
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Remission was maintained in all but four (12%) patients who relapsed within 19 to 39 months after initial response.
  • [MeSH-minor] Adolescent. Adult. Cyclophosphamide / therapeutic use. Female. Humans. Male. Middle Aged. Prospective Studies. Time. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lupus.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 1984 Apr;25(4):689-95 [6482173.001]
  • [Cites] N Engl J Med. 1986 Mar 6;314(10):614-9 [3511372.001]
  • [Cites] Am J Med. 1987 Nov;83(5):877-85 [3674094.001]
  • [Cites] Lancet. 1992 Sep 26;340(8822):741-5 [1356175.001]
  • [Cites] Clin Exp Rheumatol. 1992 Sep-Oct;10(5):541-7 [1458710.001]
  • [Cites] Ann Intern Med. 1996 Oct 1;125(7):549-57 [8815753.001]
  • [Cites] Kidney Int. 1996 Dec;50(6):2047-53 [8943489.001]
  • [Cites] Kidney Int. 1997 Apr;51(4):1188-95 [9083285.001]
  • [Cites] J Am Soc Nephrol. 2005 Apr;16(4):1076-84 [15728784.001]
  • [Cites] Lupus. 2005;14(10):856-8 [16302683.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2219-28 [16306519.001]
  • [Cites] Arthritis Rheum. 2006 Feb;54(2):421-32 [16453282.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1321-7 [17408395.001]
  • [Cites] Lupus. 2007;16(11):887-95 [17971362.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Jan;3(1):46-53 [18003764.001]
  • [Cites] Ren Fail. 2008;30(9):865-9 [18925525.001]
  • [Cites] J Am Soc Nephrol. 2009 May;20(5):1103-12 [19369404.001]
  • [Cites] Ann Rheum Dis. 2010 Jan;69(1):61-4 [19155235.001]
  • [Cites] Arthritis Rheum. 2010 Jan;62(1):211-21 [20039429.001]
  • [Cites] Clin Exp Rheumatol. 2010 Jan-Feb;28(1):83-6 [20346244.001]
  • [Cites] Nephrol Dial Transplant. 2010 Dec;25(12):3939-48 [20538787.001]
  • [Cites] Kidney Int. 2000 Jan;57(1):258-64 [10620207.001]
  • [Cites] N Engl J Med. 2000 Oct 19;343(16):1156-62 [11036121.001]
  • [Cites] Am J Kidney Dis. 2001 Aug;38(2):256-64 [11479150.001]
  • [Cites] Ann Intern Med. 2001 Aug 21;135(4):248-57 [11511139.001]
  • [Cites] Rheumatology (Oxford). 2002 Jul;41(7):780-6 [12096228.001]
  • [Cites] Rheumatology (Oxford). 2002 Aug;41(8):876-82 [12154204.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2121-31 [12209517.001]
  • [Cites] J Rheumatol. 2002 Oct;29(10):2129-35 [12375322.001]
  • [Cites] Lupus. 2003;12(8):630-2 [12945723.001]
  • [Cites] J Am Soc Nephrol. 2004 Feb;15(2):241-50 [14747370.001]
  • [Cites] Rheumatology (Oxford). 2004 Mar;43(3):377-80 [14963204.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):971-80 [14999109.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1271-7 [7138600.001]
  • (PMID = 21059275.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  • [Other-IDs] NLM/ PMC3046515
  •  go-up   go-down


83. Sgrulletta R, Lambiase A, Micera A, Bonini S: Corneal ulcer as an atypical presentation of ocular cicatricial pemphigoid. Eur J Ophthalmol; 2007 Jan-Feb;17(1):121-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients 1 and 2 were referred to the authors' clinic for corneal ulcer while Patient 3 for relapsed epithelial defects.
  • [MeSH-minor] Administration, Topical. Adult. Conjunctiva / pathology. Epithelium, Corneal / pathology. Female. Fibrosis. Glucocorticoids / administration & dosage. Humans. Male. Middle Aged


84. Wedlake LJ, Thomas K, Lalji A, Blake P, Khoo VS, Tait D, Andreyev HJ: Predicting late effects of pelvic radiotherapy: is there a better approach? Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1163-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moderate sustained acute (cumulative) toxicity might predict severe late effects better than peak reaction.
  • METHODS AND MATERIALS: To determine prospectively whether peak or cumulative gastrointestinal (GI) acute symptoms better predict late symptoms in patients receiving pelvic radiotherapy.
  • 100 were excluded due to lack of follow-up data at one year resulting from death, too ill, stoma, relapsed, non-response or withdrawal.
  • Univariate analysis revealed a significant association between cumulative acute symptom scores and scores at 1 year (p < 0.001), which was dose-independent (p < 0.001).
  • Acute peak and 1-year scores were not associated (p = 0.431).
  • The correlation coefficient between cumulative acute symptoms and symptoms at 1 year was 0.367 and for peak acute symptoms was weaker at 0.057.
  • CONCLUSION: Cumulative acute symptoms are more predictive of late symptoms than peak acute changes in score.
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Body Mass Index. Female. Humans. Male. Middle Aged. Pelvis. Prospective Studies. ROC Curve. Radiotherapy Dosage. Smoking / adverse effects. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20231077.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


85. Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, Humm JL, Xu H, Wolden SL, Souweidane MM, Larson SM, Cheung NK: Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol; 2010 May;97(3):409-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the addition of compartmental intrathecal antibody-based radioimmunotherapy (cRIT) in patients with recurrent metastatic central nervous system (CNS) neuroblastoma following surgery, craniospinal irradiation, and chemotherapy.
  • Twenty one patients treated for recurrent neuroblastoma metastatic to the CNS, received a cRIT-containing salvage regimen incorporating intrathecal (131)I-monoclonal antibodies (MoAbs) targeting GD2 or B7H3 following surgery and radiation.
  • One patient with a 7-year history of metastatic neuroblastoma is in remission from MLL-associated secondary leukemia.
  • This is significantly improved to published results with non-cRIT based where relapsed CNS NB has a median time to death of approximately 6 months.
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Administration Schedule. Female. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans. Injections, Spinal. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Time Factors. Tomography, Emission-Computed, Single-Photon / methods. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1990 Oct;62(4):637-42 [2223581.001]
  • [Cites] J Natl Cancer Inst. 1986 Sep;77(3):739-45 [3091900.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):2020-3 [1432165.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):101-11 [9266446.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3053-60 [9738575.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4363-7 [9766665.001]
  • [Cites] Clin Cancer Res. 1996 Jun;2(6):963-72 [9816257.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9 [10363850.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jul;45(1):68-71 [15770641.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Oct;20(5):534-46 [16248769.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(3):271-6 [16400336.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5271-6 [17114661.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5465-70 [18048828.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):182-9 [18287339.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3275s-3280s [10541375.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:263-9; discussion 269-70 [10911919.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1510-9 [11301399.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4048-54 [11358824.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):194-6 [11464881.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):895-906 [12721768.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):155-65 [12833468.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jul;25(7):515-9 [12847316.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):511-3 [1591076.001]
  • (PMID = 19890606.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / FDA-KK-01A2; United States / NCI NIH HHS / CA / R21 CA117076-02; United States / NCI NIH HHS / CA / P01 CA033049-23; United States / NCI NIH HHS / CA / R21 CA089936-02; United States / FDA HHS / FD / FD003089; United States / NCI NIH HHS / CA / R21 CA089936; United States / FDA HHS / FD / R01 FD003089; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / CA106450; United States / NCI NIH HHS / CA / R21 CA117076; United States / NCI NIH HHS / CA / CA89935; United States / NCI NIH HHS / CA / CA117076; United States / NCI NIH HHS / CA / P01 CA106450; United States / NCI NIH HHS / CA / CA89936; United States / NCI NIH HHS / CA / R21 CA089935-02; United States / NCI NIH HHS / CA / P01 CA106450-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS250577; NLM/ PMC3533371
  •  go-up   go-down


86. Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, Suzuki T, Kobayashi Y, Watanabe T, Azuma T, Mori M, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Ono C, Ohata J: Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci; 2010 Aug;101(8):1840-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inotuzumab ozogamicin (CMC-544), an antibody-targeted chemotherapeutic agent composed of an anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic antibiotic, specifically targets the CD22 antigen present in >90% of B-lymphoid malignancies, rendering it useful for treating patients with B-cell non-Hodgkin lymphoma (B-NHL).
  • Eligible patients had relapsed or refractory CD22-positive B-NHL without major organ dysfunction.
  • Inotuzumab ozogamicin was well tolerated at doses up to 1.8 mg/m(2) and showed preliminary evidence of activity in relapsed or refractory follicular lymphoma pretreated with rituximab-containing therapy, warranting further investigations.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Rituximab

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20491780.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00717925
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Inotuzumab Ozogamicin; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


87. Trapero M, García-Buey L, Muñoz C, Vitón M, Moreno-Monteagudo JA, Borque MJ, Quintana NE, Moreno-Otero R: Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C. Rev Esp Enferm Dig; 2005 Jul;97(7):481-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients (mean age 45 +/- 8 years) completed treatment and follow-up: 12 (43%) achieved a sustained virological response (SVR), 13 relapsed after end of treatment (47%), and only 3 (10%) were non-responders.
  • [MeSH-minor] Adult. Analysis of Variance. Chi-Square Distribution. Cytokines / immunology. Data Interpretation, Statistical. Drug Therapy, Combination. Female. Flow Cytometry. Follow-Up Studies. Genotype. Hepacivirus / genetics. Humans. Longitudinal Studies. Male. Middle Aged. Prospective Studies. Recombinant Proteins. T-Lymphocytes / immunology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16262527.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Cytokines; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


88. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM: T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood; 2009 Dec 10;114(25):5136-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
  • The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood.
  • Only 8 of 123 relapsed patients survive.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Cytogenetic Analysis. Female. Fusion Proteins, bcr-abl / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prospective Studies. Remission Induction. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4352-6 [19635999.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Apr;16(2):245-99, v [12094473.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Dec;16(4):671-83 [14592650.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Blut. 1990 Jan;60(1):48-51 [2297585.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Mar;52(1):79-84 [2009514.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1832-3 [8892689.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Blood. 2006 Jan 15;107(2):473-9 [16179376.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):989-95 [16633362.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):764-7 [18401411.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):153-68 [18691165.001]
  • [Cites] Blood. 2009 Jan 1;113(1):100-7 [18838613.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Haematologica. 2001 Jul;86(7):675-92 [11454522.001]
  • (PMID = 19828704.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / G8223452; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC2792210
  •  go-up   go-down


89. Krishnan A, Palmer JM, Zaia JA, Tsai NC, Alvarnas J, Forman SJ: HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant; 2010 Sep;16(9):1302-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Randomized trials comparing autologous stem cell transplant (ASCT) to conventional chemotherapy have demonstrated superior survival among HIV-negative ASCT patients with relapsed non-Hodgkin lymphoma (NHL).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1027-32 [18309938.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Blood. 1992 Jul 1;80(1):8-20 [1319239.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Transplantation. 2006 Jun 27;81(12):1658-61 [16794531.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • (PMID = 20353830.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA033572; United States / NCI NIH HHS / CA / P01 CA030206-260020; United States / NCI NIH HHS / CA / CA030206-250020; United States / NCI NIH HHS / CA / CA030206-260020; United States / NCI NIH HHS / CA / CA107399-04; United States / NCI NIH HHS / CA / P50 CA107399-04; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P01 CA030206-250020; United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS192932; NLM/ PMC2916976
  •  go-up   go-down


90. Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, Sailler L, Delaunay C, Sadoun A, Guillevin L, French Vasculitis Study Group: Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum; 2008 Jan;58(1):308-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: IVIGs induced complete remissions of relapsed ANCA-associated vasculitides in 13 of 22 patients at month 9.
  • [MeSH-minor] Adult. Aged. Anti-Inflammatory Agents / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / therapeutic use. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PREDNISONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2008 Jul;58(7):2211-2; author reply 2212 [18576349.001]
  • (PMID = 18163506.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00307658
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Antineutrophil Cytoplasmic; 0 / Immunoglobulins, Intravenous; VB0R961HZT / Prednisone
  •  go-up   go-down


91. Tan P, Marotta P, Ghent C, Adams P: Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int; 2005 Aug;25(4):728-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 41% of non-LT patients relapsed on maintenance treatment, and 41% of non-LT patients relapsed when withdrawn from treatment.
  • [MeSH-minor] Adult. Canada / epidemiology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Odds Ratio. Prednisolone / therapeutic use. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Rate. Transaminases / analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Autoimmune Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998422.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9PHQ9Y1OLM / Prednisolone; EC 2.6.1.- / Transaminases; MRK240IY2L / Azathioprine
  •  go-up   go-down


92. Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, Dalifard I, Hacene K, Pichon MF: CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol; 2006 Aug;17(8):1234-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: For 553 stage IIC-IV patients, 459 (83.0%) relapsed and 444 (80.3%) died from cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766592.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


93. Schleuning M, Judith D, Jedlickova Z, Stübig T, Heshmat M, Baurmann H, Schwerdtfeger R: Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant; 2009 May;43(9):717-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.
  • The underlying diagnoses were relapsed or refractory T-ALL (n=3), AML with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) or mixed-lineage leukemia-partial tandem duplication (MLL-PTD; n=10; 5 with refractory disease) and CML in refractory myeloid blast crisis (n=2).
  • Grades II-IV acute GVHD occurred in 21% and chronic GVHD in 30% of patients.
  • Three patients with FLT3-ITD+ AML relapsed after a median of 112 days.
  • [MeSH-major] Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation / methods. Leukemia / therapy. Mycophenolic Acid / analogs & derivatives. Sirolimus / administration & dosage
  • [MeSH-minor] Adult. Calcineurin Inhibitors. Cohort Studies. Female. Humans. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Premedication / methods. Salvage Therapy / methods. Survival Rate. Transplantation, Homologous. Young Adult

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011660.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


94. Zanetti D, Campovecchi CB, Balzanelli C, Pasini S: Paroxysmal positional vertigo after cochlear implantation. Acta Otolaryngol; 2007 May;127(5):452-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All of them relapsed within 3 months after an initially successful repositioning maneuver, and finally recovered after the second one.
  • PATIENTS AND METHODS: Among 32 adult patients who received a Nucleus CI, 4 suffered from PPV on the basis of Dix-Hallpike's maneuvers.
  • PPV developed 1-12 months after CI surgery in the posterior canal and relapsed within 3 months.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Dizziness and Vertigo.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453469.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


95. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol; 2010 Mar 20;28(9):1591-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
  • This phase I study assessed the safety, pharmacokinetics, recommended phase II dose and efficacy of KW-0761 in patients with relapsed CCR4-positive adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL).
  • Other treatment-related grade 3 to 4 toxicities were lymphopenia (n = 10), neutropenia (n = 3), leukopenia (n = 2), herpes zoster (n = 1), and acute infusion reaction/cytokine release syndrome (n = 1).
  • CONCLUSION: KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL or PTCL.
  • [MeSH-major] Antibodies, Anti-Idiotypic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy. Receptors, CCR4 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Aug 10;28(23):e404-5; author reply e406 [20566994.001]
  • (PMID = 20177026.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Receptors, CCR4; 0 / mogamulizumab
  •  go-up   go-down


96. Huang HQ, Cai QC, Shi YX, Lin XB, Wei J, Guo Y, Pan ZH: [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)]. Ai Zheng; 2006 Aug;25(8):1023-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 75% of the cases achieved CR while 4.17% were progression of disease (PD) and 16.67% were relapsed during the median follow-up time of 12 (2-60) months.
  • [MeSH-minor] Adolescent. Adult. CD4-CD8 Ratio. CD4-Positive T-Lymphocytes / immunology. Cytokine-Induced Killer Cells / transplantation. Cytokines / metabolism. Female. Follow-Up Studies. Humans. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Male. Middle Aged. Remission Induction. Th1 Cells / immunology. Th2 Cells / immunology. Thymus Extracts / therapeutic use. Transplantation Conditioning. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965687.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / TFX; 0 / Thymus Extracts
  •  go-up   go-down


97. Joly P: The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol; 2006 Oct;55(4):632-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all, 3 patients maintained hair regrowth and 3 relapsed.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Alopecia totalis.
  • Genetic Alliance. consumer health - Alopecia universalis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17010743.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


98. Li SM, Zhang WH, Bai P, Li HJ, Zhang R, Wu LY: [Clinical analysis of 20 patients with vaginal intraepithelial neoplasia]. Zhonghua Fu Chan Ke Za Zhi; 2009 Apr;44(4):277-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three cases (included 1 post-irradiated and 2 post-operative) were relapsed after treatment, but still be controlled completely by radiotherapy or surgery.
  • Surgery and radiotherapy was equally effective to control VAIN, and then follow-up post-treatment should be closely to detect, diagnose and treat recurrent VAIN as soon as possible after treatment.
  • [MeSH-minor] Adult. Aged. Biopsy. Brachytherapy. Female. Follow-Up Studies. Humans. Laser Therapy. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Papanicolaou Test. Precancerous Conditions / mortality. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Precancerous Conditions / therapy. Prognosis. Retrospective Studies. Survival Rate. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology. Vagina / pathology. Vagina / surgery. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570466.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Pradeepkumar AS, Thankappan KR, Nichter M: Smoking among tuberculosis patients in Kerala, India: proactive cessation efforts are urgently needed. Int J Tuberc Lung Dis; 2008 Oct;12(10):1139-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although 87% of patients had quit smoking soon after diagnosis, 36% had relapsed by 6 months post treatment.
  • One third relapsed during the first 3 months of treatment and another third during the next 3 months of treatment.
  • [MeSH-minor] Adult. Antitubercular Agents / administration & dosage. Directly Observed Therapy. Humans. India / epidemiology. Interviews as Topic. Logistic Models. Male. Middle Aged. Recurrence. Risk Factors. Sampling Studies

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Tuberc Lung Dis. 2008 Oct;12(10):1103 [18812035.001]
  • (PMID = 18812043.001).
  • [ISSN] 1027-3719
  • [Journal-full-title] The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • [ISO-abbreviation] Int. J. Tuberc. Lung Dis.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / R01 TW005969-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


100. Al-Mulhim FA: Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma. Saudi Med J; 2005 Jan;26(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance images after completion of treatment showed residual BM infiltration in 6 out of 17 cases who previously had positive MR images and only one case of them had a positive BM biopsy with a significant difference between both methods and all of them relapsed within 6 months (p=0.034).
  • [MeSH-minor] Adolescent. Adult. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Saudi Med J. 2005 May;26(5):898
  • (PMID = 15756349.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down






Advertisement